WFMZ-TV

Global Spinal Cord Stimulation (SCS) Market 2019-2023: Rise in Adoption of Surgical Robots / Proclaim XR / 7D Surgical System / Attempts by Major Players to Strengthen Presence ...

DUBLIN, Dec. 9, 2019 /PRNewswire/ -- The "Global Spinal Cord Stimulation (SCS) Market: Size, Trends & Forecasts (2019-2023)" report has been added to ResearchAndMarkets.com's offering. Global Spinal ...
Seeking Alpha

FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy

The new indication for Abbott's Proclaim™ XR SCS system provides a non-medication option for people with painful diabetic peripheral neuropathy Spinal cord stimulation is proven to be more effective ...
Healio

FDA approves spinal cord stimulation system for diabetic pain

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the Proclaim XR spinal cord stimulation system to treat painful diabetic peripheral ...
Nasdaq

Abbott Says FDA Oks Proclaim XR Spinal Cord Stimulation System To Treat DPN

(RTTNews) - Abbott Laboratories, Inc. (ABT) announced Thursday that the U.S. Food and Drug Administration (FDA) has approved its Proclaim XR spinal cord stimulation (SCS) system to treat painful ...
Medscape

FDA Clears Spinal Cord Stimulator for Diabetic Neuropathy

The US Food and Drug Administration has approved Abbott's Proclaim XR spinal cord stimulation (SCS) system for the treatment of patients with diabetic peripheral neuropathy (DPN), the company ...
Monthly Prescribing Reference

Abbott’s SCS System Cleared for Patients With Painful Diabetic Peripheral Neuropathy

It was originally approved in 2019 for the treatment of chronic pain. The Food and Drug Administration (FDA) has approved the Proclaim™ XR spinal cord stimulation (SCS) system for the treatment of ...